The dual SYK/JAK inhibitor cerdulatinib is under evaluation in a phase I/II trial in patients with R/R CLL or NHL, including PTCL (NCT01994382). Here, SYK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.